Oragenics Inc

NYSE American:OGENUnited States

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

Contact Information

Headquarters

1990 MAIN STREET, SUITE 750SARASOTA, FL, United States 34236

Phone

813-286-7900

Fax

813-286-7904

Executives

Interim Executive Chairman of the Board

Charles Pope

President, Interim Principal Executive Officer

Michael Redmond

Chief Financial Officer, Treasurer, Secretary

Janet Huffman

Senior Vice President Discovery Research

Martin Handfield

Chief Medical Officer

James Kelly